These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32578241)

  • 1. Semiparametric copula-based analysis for treatment effects in the presence of treatment switching.
    Huang CH; Chen YH; Wang JL; Wang M
    Stat Med; 2020 Sep; 39(22):2936-2948. PubMed ID: 32578241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum likelihood analysis of semicompeting risks data with semiparametric regression models.
    Chen YH
    Lifetime Data Anal; 2012 Jan; 18(1):36-57. PubMed ID: 21850528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semiparametric copula method for semi-competing risks data subject to interval censoring and left truncation: Application to disability in elderly.
    Sun T; Li Y; Xiao Z; Ding Y; Wang X
    Stat Methods Med Res; 2023 Apr; 32(4):656-670. PubMed ID: 36735020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixture regression models for the gap time distributions and illness-death processes.
    Huang CH
    Lifetime Data Anal; 2019 Jan; 25(1):168-188. PubMed ID: 29374789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A joint frailty-copula model between tumour progression and death for meta-analysis.
    Emura T; Nakatochi M; Murotani K; Rondeau V
    Stat Methods Med Res; 2017 Dec; 26(6):2649-2666. PubMed ID: 26384516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical analysis of illness-death processes and semicompeting risks data.
    Xu J; Kalbfleisch JD; Tai B
    Biometrics; 2010 Sep; 66(3):716-25. PubMed ID: 19912171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copula-based semiparametric regression method for bivariate data under general interval censoring.
    Sun T; Ding Y
    Biostatistics; 2021 Apr; 22(2):315-330. PubMed ID: 31506682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint modeling approach for semicompeting risks data with missing nonterminal event status.
    Hu C; Tsodikov A
    Lifetime Data Anal; 2014 Oct; 20(4):563-83. PubMed ID: 24430204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating survival and association in a semicompeting risks model.
    Lakhal L; Rivest LP; Abdous B
    Biometrics; 2008 Mar; 64(1):180-8. PubMed ID: 17645782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copula-based semiparametric models for spatiotemporal data.
    Tang Y; Wang HJ; Sun Y; Hering AS
    Biometrics; 2019 Dec; 75(4):1156-1167. PubMed ID: 31009058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semiparametric frailty models for zero-inflated event count data in the presence of informative dropout.
    Diao G; Zeng D; Hu K; Ibrahim JG
    Biometrics; 2019 Dec; 75(4):1168-1178. PubMed ID: 31106400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome.
    Diao G; Zeng D; Hu K; Ibrahim JG
    Stat Med; 2017 Sep; 36(22):3475-3494. PubMed ID: 28560768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On shared gamma-frailty conditional Markov model for semicompeting risks data.
    Li J; Zhang Y; Bakoyannis G; Gao S
    Stat Med; 2020 Oct; 39(23):3042-3058. PubMed ID: 32567141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression modeling of semicompeting risks data.
    Peng L; Fine JP
    Biometrics; 2007 Mar; 63(1):96-108. PubMed ID: 17447934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Semi-stationary Copula Model Approach for Bivariate Survival Data with Interval Sampling.
    Zhu H; Wang MC
    Int J Biostat; 2015 May; 11(1):151-73. PubMed ID: 25720090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's τ.
    Weber EM; Titman AC
    Stat Med; 2019 Feb; 38(5):703-719. PubMed ID: 30311243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semiparametric accelerated failure time cure rate mixture models with competing risks.
    Choi S; Zhu L; Huang X
    Stat Med; 2018 Jan; 37(1):48-59. PubMed ID: 28983935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.
    Sofeu CL; Emura T; Rondeau V
    Biom J; 2021 Feb; 63(2):423-446. PubMed ID: 33006170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semiparametric regression analysis of interval-censored competing risks data.
    Mao L; Lin DY; Zeng D
    Biometrics; 2017 Sep; 73(3):857-865. PubMed ID: 28211951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.